Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
Open Access
- 25 September 2018
- journal article
- editorial
- Published by Wiley in Thoracic Cancer
- Vol. 9 (11), 1522-1524
- https://doi.org/10.1111/1759-7714.12872
Abstract
Nivolumab, an anti‐PD‐1 antibody, has been shown to be effective in many cancers, such as malignant melanoma and lung cancer; however, nivolumab therapy can result in pseudoprogression. Diffuse alveolar hemorrhage (DAH) is persistent or recurrent pulmonary hemorrhage as a result of drugs, autoimmune diseases, or infections. DAH with pseudoprogression during nivolumab administration has rarely been reported. Herein, we describe our experience with one such case. A 41‐year‐old woman exhibited bloody sputum and ground glass opacities in the lungs along with tumor growth during nivolumab therapy for multiple lung metastases of malignant melanoma. We diagnosed DAH with pseudoprogression as a result of nivolumab and administered steroid therapy. The DAH subsequently improved and the tumor shrank. This case illustrates that nivolumab can cause DAH with pseudoprogression, which can be controlled by steroid therapy. Thus, if bloody sputum and ground glass opacities in the lungs are observed with tumor growth during nivolumab administration, steroid therapy should be considered to control DAH with pseudoprogression.Keywords
This publication has 10 references indexed in Scilit:
- Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case reportBMC Cancer, 2017
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabJournal of Clinical Oncology, 2016
- Pseudoprogression and Immune-Related Response in Solid TumorsJournal of Clinical Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationThe New England Journal of Medicine, 2015
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- Update on Diffuse Alveolar Hemorrhage and Pulmonary VasculitisImmunology and Allergy Clinics of North America, 2012
- Diffuse Alveolar HemorrhageSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009